Welcome to our dedicated page for Cannara Biotech news (Ticker: LOVFF), a resource for investors and traders seeking the latest updates and insights on Cannara Biotech stock.
Cannara Biotech Inc. reports developments as a vertically integrated Canadian cannabis producer trading in the U.S. as LOVFF. The company cultivates and produces premium-grade cannabis and cannabis-derivative products for the Canadian market from two large Québec facilities, with disclosed potential annual cultivation output of 100,000 kilograms.
Recurring news includes operating and financial results, cultivation-yield and capacity updates, Valleyfield facility expansion, credit-facility amendments, asset optimization, product-category launches, provincial retail listings, and equity incentive grants. Company updates also cover exchange-listing status, including its graduation to the Toronto Stock Exchange, and governance or capital-structure actions tied to its growth plans.
Cannara Biotech (TSX: LOVE | OTCQX: LOVFF) announced an uplisting to the Toronto Stock Exchange and highlighted large-scale production capacity in Québec. The company owns two mega facilities totaling over 1,600,000 sq. ft. with 100,000 kg potential annualized cultivation output and low electricity costs supporting efficient operations.
The company positions itself as a vertically integrated producer of premium cannabis and cannabis-derivative products, citing award-winning SKUs and national retail reach as growth levers.
Cannara Biotech (OTCQB: LOVFF), a vertically integrated cannabis producer, has announced plans to settle approximately $6.2 million of debt through a share issuance. The settlement includes $4.7 million in principal and $1.5 million in accrued interest under its convertible debenture with Olymbec Investments.
The company will issue 3,462,763 common shares at a deemed price of $1.80 per share, with 851,652 shares representing interest payment. Upon completion, Olymbec will hold approximately 25.47% of Cannara's outstanding shares. The transaction requires TSX Venture Exchange approval and qualifies for exemption from minority shareholder approval requirements.
Additionally, Cannara granted 40,000 stock options to Bristol Capital for investor relations services, exercisable at $1.80 per share until April 25, 2028.
Cannara Biotech (OTCQB: LOVFF), a vertically integrated cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft., has announced new incentive awards following its fiscal year-end on August 31, 2025.
The company granted 3,625,000 stock options to employees at an exercise price of $1.44 per share, vesting monthly over three years with a ten-year expiration. Additionally, 145,000 restricted share units (RSUs) were awarded to board members, vesting fully after two years. The announcement comes after five consecutive years of revenue growth in their cannabis operations.
Cannara Biotech (OTCQB: LOVFF) has announced significant amendments to its BMO credit facility, including a $10 million upsize to support strategic capital investments at its Valleyfield facility. The expanded facility includes a new Capital Expenditures Facility available through July 2026 with a 10-year amortization schedule.
The company has achieved multiple interest rate reductions, lowering its overall cost of debt from over 8% in 2024 to below 6%. Additionally, Cannara eliminated a limited recourse guarantee, resulting in annual interest expense savings of approximately $375,000.
The funding will support Valleyfield's post-harvest expansion, including new drying, freezing, trimming, and packaging capabilities, advancing toward the company's goal of 100,000 kg annual production capacity.
Cannara Biotech (OTCQB: LOVFF), a vertically integrated cannabis producer with two mega facilities in Québec, has completed the sale of a non-core building under construction and land at its Valleyfield site for $5.5 million. The assets, previously classified as "held for sale" with a carrying value of $4,951,165, were part of the company's asset optimization plan announced in January 2024.
The net proceeds of $5.45 million will be used to reduce the principal balance of Cannara's existing term loan. The transaction aligns with the company's strategy to unlock value from underutilized assets while maintaining focus on its core cannabis operations.
Cannara Biotech (OTCQB:LOVFF) reported record-breaking financial results for Q3 2025, with total revenues reaching $27.3 million, a 40% increase year-over-year. The company achieved its seventeenth consecutive quarter of positive Adjusted EBITDA, which rose 173% to $7.6 million.
Key highlights include a 110% increase in gross profit to $12.1 million, improved gross margins of 44% (up from 29%), and record operating cash flow of $13.9 million. The company achieved a significant 26% yield improvement across its facilities, increasing annual capacity from 39,500 kg to 50,000 kg, meeting its Fiscal 2026 target ahead of schedule.
Additionally, Cannara secured approval for 5 SKUs in Quebec's upcoming vape category launch, representing 20% of all accepted in-store SKUs, and reduced its BMO credit facility interest rate to below 6%.
[ "Record revenue of $27.3M, up 40% year-over-year", "Gross profit increased 110% to $12.1M with margins expanding to 44%", "Record Adjusted EBITDA of $7.6M, up 173% year-over-year", "26% yield improvement achieved without additional capital expenditures", "Operating cash flow increased 221% to $13.9M", "Secured 20% market share in Quebec's new vape category", "Credit facility interest rate reduced to below 6%", "Earnings per share increased to $0.05 from $0.02 year-over-year" ]Cannara Biotech (OTCQB: LOVFF) has secured preliminary acceptance from SQDC for 5 vape cartridge products to be distributed across all Québec retail stores starting November 2025. The company's products will represent 20% of the 25 vape cartridge SKUs planned for in-store distribution by year-end.
The company, which operates two mega facilities in Québec totaling over 1,650,000 sq. ft., will introduce both live resin and live rosin vape cartridges. This launch marks Québec's entry into the vape cartridge market, with significant potential given that the SQDC reported $741.5 million in revenue for 2024. Market research indicates 25% of Québec consumers used vapes in the past year, with vape segments representing approximately 15% of total sales in other major Canadian provinces.
Cannara Biotech Inc. (OTCQB: LOVFF), a vertically integrated cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft., has scheduled its fiscal Q3 2025 earnings release for July 28, 2025.
The financial results for the quarter ended May 31, 2025, will be released at 7:00 a.m. ET, followed by an earnings webcast at 11:00 a.m. ET. CFO Nicholas Sosiak will host the webcast, which will include prepared remarks and a Q&A session. Investors can submit questions in advance via email to investors@cannara.ca.